1119276-80-0

1119276-80-0 structure

Name: Lifitegrast sodium
Chemical Name: sodium,(2S)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-3,4-dihydro-1H-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoate
CAS Number: 1119276-80-0
Molecular Formula: C₂₉H₂₃Cl₂N₂NaO₇S
Molecular Weight: 637.46300
Catalog: Signaling Pathways Cytoskeleton Integrin
Create Date: 2017-05-10 20:23:38
Modify Date: 2024-01-16 17:26:46
Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast sodium can be used for researching dry eye disease[1].

Name	sodium,(2S)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-3,4-dihydro-1H-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoate
Synonyms	Lifitegrast sodium UNII-QG18FLP1KP SAR-1118-023

Description	Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast sodium can be used for researching dry eye disease[1].
Related Catalog	Research Areas >> Inflammation/Immunology Signaling Pathways >> Cytoskeleton >> Integrin
Target	αLβ2
In Vitro	Lifitegrast (SAR 1118) inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), thus lessening overall inflammatory responses[1]. Lifitegrast strongly inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM[1].
In Vivo	Lifitegrast has potent anti-inflammatory activity on corneal inflammation induced by antibiotic-killed P. aeruginosa and S. aureus in the presence of a silicone hydrogel lens with the optimal application being a 1% solution applied either 2 or 3 times prior[2].
References	[1]. Perez VL, et al. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. Ocul Surf. 2016 Apr;14(2):207-15. [2]. Sun Y, et al. Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). J Ocul Pharmacol Ther. 2013 May;29(4):395-402. [3]. Rao VR, et al. Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin(STZ) model of diabetic retinopathy (DR). Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5198-204.

Molecular Formula	C₂₉H₂₃Cl₂N₂NaO₇S
Molecular Weight	637.46300
Exact Mass	636.05000
PSA	148.69000
LogP	6.23330

1119276-80-0	1144097-30-2
68057-99-8	6100-16-9
79060-88-1	30605-57-3
61538-65-6	71376-34-6
91840-27-6	81075-52-7
1158522-08-7	940364-43-2
134104-43-1	1306739-69-4
131615-57-1	6906-52-1
930439-75-1	1018584-77-4
1375289-11-4	849349-65-1